Sheng-xiang Ren

Learn More
OBJECTIVE To explore the diagnostic values of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in patients with hilar and mediastinal tumors. METHODS A total of 837 patients with chest CT or PET/CT confirmed mediastinal/hilar lymphadenopathy and or tumors in (or around) the trachea or bronchi, were evaluated by EBUS-TBNA(More)
OBJECTIVE To improve the diagnosis of pulmonary mucosa associated lymphoid tissue (PMALT) lymphoma. METHOD The clinical and radiographic data of 13 cases of pathology confirmed PMALT lymphoma admitted from June 1998 to June 2006 were respectively analyzed. RESULTS There were 9 males and 4 females, with an average age of 55 years. The course of the(More)
OBJECTIVE Experimental evidence suggests that the overexpression of breast cancer-specific tumor suppressor protein 1 (BRCA1) gene enhances sensitivity to docetaxel and resistance to cisplatin and ribonucleotide reductase M1 (RRM1) gene overexpression enhances resistance to gemcitabine. To further examine the effect of BRCA1 and RRM1 mRNA levels on outcome(More)
BACKGROUND Activating mutations of epidermal growth factor receptor (EGFR) could predict response to tyrosine kinase inhibitor (TKI) treatment in patients with non-small cell lung cancer (NSCLC). However, the detection of EGFR mutation is frequently challenging in clinical practice for the lack of tumor tissue. The aim of this study was to investigate the(More)
BACKGROUND Serum expression of cytokines may provide information about the clinical outcome of advanced non-small cell lung cancer (NSCLC) patients. This study aimed to investigate the relationship between serum cytokine levels and the clinical outcome of erlotinib treatment in a second or third line setting in patients with advanced NSCLC. METHODS A(More)
Activating mutations in epidermal growth factor receptor (EGFR) gene confer dramatic sensitivity to EGFR TKIs (Rich et al., 2004). Several large randomized phase III studies consistently showed that EGFR-TKIs, such as gefitinib, erlotinib or afatinib achieved significantly higher response rates and longer progression-free survival (PFS) compared to standard(More)
BACKGROUND Chemotherapy is the mainstay of treatment for the majority of patients with advanced non- small cell lung cancer (NSCLC) without driver mutations and many receive therapies beyond first-line. Second- line chemotherapy has been disappointing both in terms of response rate and survival and we know relatively little about the prognostic factors. (More)
OBJECTIVE To investigate the ultrastructural features of sputum deposition (SD) and its value in the diagnosis of pulmonary alveolar proteinosis (PAP). METHODS Seven patients with PAP diagnosed by lung biopsy and cytology were enrolled in this study. The patients consisted of 5 men and 2 women, whose median age was 48 years (range 36 to 73). SD and(More)
OBJECTIVE To investigate the impact of erlotinib as a second or third line treatment on the symptoms and quality of life (QOL) in patients with advanced non-small cell lung cancer (NSCLC). METHODS Fifty patients with stage III b and IV NSCLC, treated previously with at least one regimen of platinum-based chemotherapy, received 150 mg of erlotinib orally,(More)